Skip to content

A Novel Optical Spectral Imaging System for Imaging Breast Tumor Margins

A Novel Optical Spectral Imaging System for Imaging Breast Tumor Margins

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01372631
Enrollment
218
Registered
2011-06-14
Start date
2011-04-30
Completion date
2017-04-01
Last updated
2021-02-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Keywords

Reduction mammoplasty, mastectomy, partial mastectomy, lumpectomy, breast conserving surgery, breast cancer

Brief summary

The goal of this research is to further develop novel optical assay systems for intra operative assessment of tumor margins in partial mastectomy or mastectomy specimens.

Detailed description

The goal of this research is to further develop novel optical assay systems for intra operative assessment of tumor margins in partial mastectomy or mastectomy specimens. We are seeking to establish the accuracy of first and second-generation prototypes of technologies utilizing optical spectroscopy for intra operative margin assessment in partial mastectomy or mastectomy specimens. The aims associated with this research are as follows, (1) to evaluate the device-tissue interface on reduction mammoplasty specimens from a total of 20 patients, (2) to assess random and systematic errors of the new miniature system on mastectomy specimens from a total of 40 patients (3) to test the sensitivity, and specificity of the miniature spectral imaging system for margin assessment on excised partial mastectomy or mastectomy specimens from a total of 150 patients undergoing breast conserving surgery. Last patient's surgery took place in 2017 and recruitment remained open. Later the team encountered staffing issues; therefore the study status was updated to suspended. We recently made the decision to no longer attempt to enroll the remaining 2 subjects and focus on the data analysis only.

Interventions

DEVICEminiature spectral imaging system

Use of miniature spectral imaging system

DEVICEBench-top optical spectrometer

Use of bench-top optical spectrometer

Use of high resolution microendoscope

Sponsors

National Institutes of Health (NIH)
CollaboratorNIH
National Institute for Biomedical Imaging and Bioengineering (NIBIB)
CollaboratorNIH
Duke University
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
DEVICE_FEASIBILITY
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients undergoing a reduction mammoplasty OR * Patients undergoing a lumpectomy mastectomy for the treatment of an invasive or non-invasive breast malignancy * Age \> 18 * Clinically detectable disease either by physical examination or radiographic studies * Patients of all ethnic and gender groups will be included. Protocol accrual will be reviewed annually to include a determination of minority and gender representation. If accrual demonstrates under-representation of any group with comparison to disease incidence in that group, appropriate measures will be undertaken to increase participation of patients of that minority or gender group * Ability to understand and the willingness to sign a written informed consent document.

Exclusion criteria

* Patients considered in vulnerable populations.

Design outcomes

Primary

MeasureTime frame
Identification of the optical signatures in breast tissueDay of procedure (less than 10 minutes)

Secondary

MeasureTime frame
Sensitivity and Specificity of the deviceDay of procedure (less than 10 minutes)

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026